
Entrada Therapeutics, Inc. (NASDAQ:TRDA – Free Report) – Investment analysts at HC Wainwright boosted their FY2026 EPS estimates for Entrada Therapeutics in a report issued on Thursday, November 12th. HC Wainwright analyst R. Selvaraju now anticipates that the company will earn ($3.99) per share for the year, up from their previous estimate of ($4.19). HC Wainwright currently has a “Neutral” rating on the stock. The consensus estimate for Entrada Therapeutics’ current full-year earnings is ($4.12) per share. HC Wainwright also issued estimates for Entrada Therapeutics’ Q4 2026 earnings at ($1.09) EPS, Q1 2027 earnings at ($0.83) EPS, Q2 2027 earnings at ($0.75) EPS, Q3 2027 earnings at ($0.82) EPS, Q4 2027 earnings at ($0.89) EPS and FY2027 earnings at ($3.29) EPS.
Entrada Therapeutics (NASDAQ:TRDA – Get Free Report) last posted its quarterly earnings data on Thursday, November 5th. The company reported ($0.94) earnings per share (EPS) for the quarter, beating the consensus estimate of ($1.01) by $0.07. The company had revenue of $0.91 million during the quarter, compared to analyst estimates of $2.30 million. Entrada Therapeutics had a negative return on equity of 64.00% and a negative net margin of 4,057.98%.
Read Our Latest Report on TRDA
Entrada Therapeutics Price Performance
Entrada Therapeutics stock opened at $5.09 on Monday. Entrada Therapeutics has a 52 week low of $4.11 and a 52 week high of $16.45. The business has a 50-day simple moving average of $5.60 and a 200 day simple moving average of $8.42. The stock has a market cap of $199.27 million, a price-to-earnings ratio of -1.33 and a beta of -0.19.
Institutional Investors Weigh In On Entrada Therapeutics
Institutional investors have recently added to or reduced their stakes in the company. BlackRock Inc. bought a new stake in shares of Entrada Therapeutics during the 2nd quarter valued at about $19,013,000. Nantahala Capital Management LLC bought a new position in Entrada Therapeutics in the second quarter worth about $2,212,232. 5AM Venture Management LLC bought a new position in Entrada Therapeutics in the second quarter worth about $29,854,949. GSA Capital Partners LLP purchased a new stake in Entrada Therapeutics in the second quarter worth about $648,000. Finally, Bank of New York Mellon Corp purchased a new stake in Entrada Therapeutics in the second quarter worth about $582,000. Hedge funds and other institutional investors own 86.39% of the company’s stock.
Insider Buying and Selling at Entrada Therapeutics
In other Entrada Therapeutics news, major shareholder Bioventures 2018 L.P. Mpm sold 28,837 shares of the firm’s stock in a transaction dated Wednesday, September 9th. The stock was sold at an average price of $7.13, for a total transaction of $205,607.81. Following the sale, the insider owned 3,885,115 shares in the company, valued at $27,700,869.95. This trade represents a 0.74% decrease in their ownership of the stock. The transaction was disclosed in a document filed with the SEC, which is available at this hyperlink. Also, major shareholder Bioventures 2014 L.P. Mpm sold 14,569 shares of the firm’s stock in a transaction dated Wednesday, August 26th. The shares were sold at an average price of $7.06, for a total value of $102,857.14. Following the transaction, the insider directly owned 4,318,348 shares in the company, valued at approximately $30,487,536.88. This represents a 0.34% decrease in their ownership of the stock. The disclosure for this sale is available in the SEC filing. In the last 90 days, insiders have sold 495,947 shares of company stock worth $3,600,470. Corporate insiders own 9.49% of the company’s stock.
About Entrada Therapeutics
Entrada Therapeutics is a biotechnology company focused on developing medicines that deliver therapeutic molecules into cells. Founded in 2016 and based in Boston, Massachusetts, the company developed its Endosomal Escape Vehicle (EEV) platform to help move drug cargo across cellular membranes and reach intracellular targets. The company’s research centers on its EEV-based oligonucleotide medicines, including programs designed to address genetic causes of neuromuscular diseases. Its development work includes candidates intended to alter RNA processing for Duchenne muscular dystrophy, with programs targeting different genetic subgroups of the disease.
Featured Articles
- Five stocks we like better than Entrada Therapeutics
- Intuitive Machines’ Business Is Taking Off—Will Its Stock Follow?
- The Next Big Thing May Not Be One Thing: Inside Lazard’s Megatrends ETF
- 3 Power and Grid Stocks That Could Keep Growing Even if AI Spending Slows
- Applied Materials Beats and Raises, But Investors Stay Unconvinced
Receive News & Ratings for Entrada Therapeutics Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Entrada Therapeutics and related companies with MarketBeat.com's FREE daily email newsletter.
